Mannkind (MNKD) Gains from Investment Securities (2010 - 2026)
Mannkind (MNKD) reported Gains from Investment Securities of $62000.0 for Q1 2026, down 70.05% year-over-year from $207000.0 in Q1 2025, and down 93.97% quarter-over-quarter from $1.0 million in Q4 2025.
Mannkind (MNKD) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Gains from Investment Securities data on file, last reported at $62000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $62000.0, down 70.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $967000.0 (down 46.31% YoY), and the FY2025 annual result was $5.4 million, down 26.25% from the prior year.
- Gains from Investment Securities retreated to $62000.0 in Q1 2026 per MNKD's latest filing, from $1.0 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $3.9 billion in Q2 2022 and troughed at -$331000.0 in Q4 2024.
- A 5-year average of $283.7 million and a median of $1.0 million in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 125.21% in 2024, then surged 410.88% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $612000.0 in 2022, then surged by 114.54% to $1.3 million in 2023, then slumped by 125.21% to -$331000.0 in 2024, then surged by 410.88% to $1.0 million in 2025, then plunged by 93.97% to $62000.0 in 2026.
- Business Quant data shows MNKD's Gains from Investment Securities at $62000.0 in Q1 2026, $1.0 million in Q4 2025, and $625340.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Mannkind | 1.13 Bn | 995.19 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 625,340.00 |
| Sep 30, 2025 | 625,340.00 |
| Jun 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 207,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Dec 31, 2024 | -331,000.00 |
| Dec 31, 2024 | -331,000.00 |
| Sep 30, 2024 | 6.14 Mn |
| Sep 30, 2024 | 6.14 Mn |
| Jun 30, 2024 | 5.63 Mn |
| Jun 30, 2024 | 5.63 Mn |
| Mar 31, 2024 | 267,990.00 |
| Mar 31, 2024 | 267,990.00 |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |